Resource impact statement

Cancer Drugs Fund reconsideration of TA296

No significant resource impact is anticipated

We do not expect this guidance to have a significant impact on resources because the population for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer is small.

The technology was previously funded through the Cancer Drugs Fund (CDF). Crizotinib will not be funded through the CDF from the date of guidance publication on 21 December 2016.

Crizotinib has been available as first-line treatment since September 2016 (see NICE’s technology appraisal guidance on crizotinib for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults).

This technology is commissioned by NHS England. Providers are NHS hospital trusts.

This page was last updated: 21 December 2016